The Role of DNA Methylation in Gastrointestinal Disease: An Expanded Review of Malignant and Non-Malignant Gastrointestinal Diseases

Esophageal, colorectal, pancreatic, hepatocellular, and gastric cancer together impact millions of patients worldwide each year, with high overall mortality rates and are increasing in incidence. Additionally, premalignant gastrointestinal diseases such as Barrett’s esophagus and inflammatory bowel disease are also increasing in incidence. However, involvement of aberrant DNA methylation in these diseases is incompletely understood, especially given recent research advancements in this field. Here, we review knowledge of this epigenetic mechanism in gastrointestinal preneoplasia and neoplasia, considering mechanisms of action, genetic and environmental factors, and CpG island methylator phenotype.

Leggi
Luglio 2024

Errors in Figure 4 and Incorrect DNA Sequencing Manufacturer

In the Original Investigation titled “Neoadjuvant Nivolumab Plus Chemotherapy Followed by Response Adaptive-Therapy for HPV+ Oropharyngeal Cancer: OPTIMA II Phase 2 Open-Label Nonrandomized Clinical Trial,” published online on June 6, 2024, in JAMA Oncology, Figure 4 contained transposed labels on the curves in panel B, and the DNA Safe-Sequencing System was not accurately attributed to Sysmex Inostics Inc. This article was corrected online.

Leggi
Luglio 2024